BR112022002632A2 - Sal e forma de cristal de composto que tem atividade de agonista do receptor s1p5 - Google Patents
Sal e forma de cristal de composto que tem atividade de agonista do receptor s1p5Info
- Publication number
- BR112022002632A2 BR112022002632A2 BR112022002632A BR112022002632A BR112022002632A2 BR 112022002632 A2 BR112022002632 A2 BR 112022002632A2 BR 112022002632 A BR112022002632 A BR 112022002632A BR 112022002632 A BR112022002632 A BR 112022002632A BR 112022002632 A2 BR112022002632 A2 BR 112022002632A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- agonist activity
- receptor agonist
- salt
- crystal form
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/10—Succinic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
- C07C65/03—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962889091P | 2019-08-20 | 2019-08-20 | |
| PCT/JP2020/031326 WO2021033729A1 (ja) | 2019-08-20 | 2020-08-19 | Ｓ１ｐ５受容体作動活性を有する化合物の塩および結晶形 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022002632A2 true BR112022002632A2 (pt) | 2022-05-03 |
Family
ID=74660224
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022002632A BR112022002632A2 (pt) | 2019-08-20 | 2020-08-19 | Sal e forma de cristal de composto que tem atividade de agonista do receptor s1p5 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US12459890B2 (https=) |
| EP (1) | EP4019496B1 (https=) |
| JP (1) | JP7409383B2 (https=) |
| KR (1) | KR102930707B1 (https=) |
| CN (1) | CN114302873A (https=) |
| AU (1) | AU2020334489C1 (https=) |
| BR (1) | BR112022002632A2 (https=) |
| CA (1) | CA3150303A1 (https=) |
| ES (1) | ES2983098T3 (https=) |
| IL (1) | IL290432A (https=) |
| MX (1) | MX2022001820A (https=) |
| MY (1) | MY207001A (https=) |
| PH (1) | PH12022550319A1 (https=) |
| TW (1) | TWI859303B (https=) |
| WO (1) | WO2021033729A1 (https=) |
| ZA (1) | ZA202201784B (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE068382T2 (hu) * | 2018-02-22 | 2024-12-28 | Ono Pharmaceutical Co | SIP5-receptor-agonista aktivitással rendelkezõ 1[[(3S)-3-metil-6-(4(4,4-trifluorbutoxi)-3,4-dihidronaftalen-2-il]metil]azetidin-3-karbonsav neurodegeneratív rendellenességek és rák kezelésére |
| US11919879B2 (en) | 2021-06-16 | 2024-03-05 | Celgene Corporation | Carboxylic acid containing azetidinyl compounds for the treatment of neurodegenerative diseases |
| KR20250114133A (ko) * | 2022-12-16 | 2025-07-28 | 셀진 코포레이션 | S1p5의 조정제로서의 헤테로시클릭 화합물 |
| WO2025119254A1 (en) | 2023-12-06 | 2025-06-12 | Ono Pharmaceutical Co., Ltd. | Method for preparing dihydronaphthalene derivative |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ234564A (en) * | 1986-11-21 | 1991-04-26 | Haessle Ab | 1-substituted benzimidazoles and pharmaceutical compositions |
| GB8725118D0 (en) * | 1987-10-27 | 1987-12-02 | Ciba Geigy Ag | Rifamycin derivatives |
| JP2005020882A (ja) | 2003-06-25 | 2005-01-20 | Matsushita Electric Works Ltd | モータアクチュエータ装置 |
| CN1874991A (zh) | 2003-08-29 | 2006-12-06 | 小野药品工业株式会社 | 能够结合s1p受体的化合物及其药物用途 |
| EP1661881B1 (en) | 2003-08-29 | 2014-12-17 | Ono Pharmaceutical Co., Ltd. | Compound capable of binding s1p receptor and pharmaceutical use thereof |
| JP2006064757A (ja) | 2004-08-24 | 2006-03-09 | Systec Kyowa:Kk | ディスプレイ固定用スタンド |
| EP2592066B1 (en) | 2004-12-13 | 2014-12-03 | Ono Pharmaceutical Co., Ltd. | Aminocarboxylic acid derivative and medical use thereof |
| AU2007212193A1 (en) | 2006-02-09 | 2007-08-16 | University Of Virginia Patent Foundation | Bicyclic sphingosine 1-phosphate analogs |
| EP2086930A2 (en) * | 2006-06-12 | 2009-08-12 | Novartis AG | Polymorphs of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide |
| UA107360C2 (en) | 2009-08-05 | 2014-12-25 | Biogen Idec Inc | Bicyclic aryl sphingosine 1-phosphate analogs |
| UA113507C2 (xx) | 2011-02-07 | 2017-02-10 | Модулятори s1p | |
| ES2852724T3 (es) | 2014-12-04 | 2021-09-14 | Ono Pharmaceutical Co | Derivados de dihidronaftaleno útiles en el tratamiento de enfermedades mediadas por S1P5 |
| ES2975689T3 (es) | 2016-01-29 | 2024-07-11 | Ono Pharmaceutical Co | Derivado de tetrahidronaftaleno |
| HUE068382T2 (hu) * | 2018-02-22 | 2024-12-28 | Ono Pharmaceutical Co | SIP5-receptor-agonista aktivitással rendelkezõ 1[[(3S)-3-metil-6-(4(4,4-trifluorbutoxi)-3,4-dihidronaftalen-2-il]metil]azetidin-3-karbonsav neurodegeneratív rendellenességek és rák kezelésére |
| TW202114983A (zh) * | 2019-08-20 | 2021-04-16 | 日商小野藥品工業股份有限公司 | Ｓ１ｐ媒介疾病的預防及／或治療劑 |
-
2020
- 2020-08-19 CN CN202080056980.0A patent/CN114302873A/zh active Pending
- 2020-08-19 PH PH1/2022/550319A patent/PH12022550319A1/en unknown
- 2020-08-19 MY MYPI2022000691A patent/MY207001A/en unknown
- 2020-08-19 BR BR112022002632A patent/BR112022002632A2/pt unknown
- 2020-08-19 TW TW109128245A patent/TWI859303B/zh active
- 2020-08-19 AU AU2020334489A patent/AU2020334489C1/en active Active
- 2020-08-19 JP JP2021540972A patent/JP7409383B2/ja active Active
- 2020-08-19 EP EP20854718.2A patent/EP4019496B1/en active Active
- 2020-08-19 KR KR1020227004458A patent/KR102930707B1/ko active Active
- 2020-08-19 CA CA3150303A patent/CA3150303A1/en active Pending
- 2020-08-19 ES ES20854718T patent/ES2983098T3/es active Active
- 2020-08-19 WO PCT/JP2020/031326 patent/WO2021033729A1/ja not_active Ceased
- 2020-08-19 MX MX2022001820A patent/MX2022001820A/es unknown
- 2020-08-19 US US17/634,505 patent/US12459890B2/en active Active
-
2022
- 2022-02-08 IL IL290432A patent/IL290432A/en unknown
- 2022-02-10 ZA ZA2022/01784A patent/ZA202201784B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL290432A (en) | 2022-04-01 |
| CA3150303A1 (en) | 2021-02-25 |
| KR102930707B1 (ko) | 2026-02-24 |
| US20220289675A1 (en) | 2022-09-15 |
| EP4019496B1 (en) | 2024-06-05 |
| JP7409383B2 (ja) | 2024-01-09 |
| MX2022001820A (es) | 2022-03-17 |
| PH12022550319A1 (en) | 2022-12-19 |
| TWI859303B (zh) | 2024-10-21 |
| ES2983098T3 (es) | 2024-10-22 |
| AU2020334489A1 (en) | 2022-03-03 |
| AU2020334489B2 (en) | 2025-10-30 |
| AU2020334489C1 (en) | 2026-03-26 |
| US12459890B2 (en) | 2025-11-04 |
| NZ785003A (en) | 2024-09-27 |
| JPWO2021033729A1 (https=) | 2021-02-25 |
| KR20220050886A (ko) | 2022-04-25 |
| ZA202201784B (en) | 2024-02-28 |
| MY207001A (en) | 2025-01-23 |
| CN114302873A (zh) | 2022-04-08 |
| EP4019496A4 (en) | 2023-01-11 |
| EP4019496A1 (en) | 2022-06-29 |
| TW202114984A (zh) | 2021-04-16 |
| WO2021033729A1 (ja) | 2021-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022002632A2 (pt) | Sal e forma de cristal de composto que tem atividade de agonista do receptor s1p5 | |
| BR112021019256A2 (pt) | Moduladores de receptor x4 de proteína g relacionado a mas e produtos e métodos relacionados | |
| BR112015020302A2 (pt) | derivado de pirazol | |
| BR112019008431A2 (pt) | aplicação de (s)-norcetamina e sal da mesma como fármaco | |
| DOP2009000237A (es) | Derivados de indazol oxadiazol sustituidos para uso como agonistas esfingosina 1-fosfato (s1p) | |
| PE20171243A1 (es) | Composicion de liberacion modificada de orlistat y acarbosa para el tratamiento de la obesidad y trastornos metabolicos relacionados | |
| GT201600010A (es) | Derivaods de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b | |
| DOP2015000245A (es) | Derivados de 3-acetilamino-1 (fenil-heteroaril-aminocarbonil o fenil-heteroaril-carbonilamino) benceno para el tratamiento de desordenes hiperproliferativos | |
| BR112017010893A2 (pt) | análogos de ácidos biliares como agonistas de fxr/tgr5 e métodos de uso dos mesmos | |
| BR112017003745A2 (pt) | inibidores de semialdeído descarboxilase de ácido alfa-amino-beta-carboximucônico | |
| UY36003A (es) | Derivados de amida, procesos de preparación y composiciones, útiles en afecciones asociadas con el receptor sub-tipo 1 de orexina. | |
| CL2016000019A1 (es) | Compuestos derivados de dihidroxifenilo deuterado o una sal de los mismos; composición farmacéutica que los comprende y su uso para el tratamiento de trastornos mediados por neurotransmisores tales como hipotensión, trastornos del sueño, enfermedad de alzheimer y depresión. | |
| BR112017016817A2 (pt) | derivados heterocíclicos formilados como inibidores de fgfr4 | |
| BR112015022092A2 (pt) | derivado de di-hidropiridazina-3,5-diona | |
| UY36875A (es) | Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades | |
| BR112018001035A2 (pt) | compostos de fenoxiacetamidas aneladas, sal farmaceuticamente aceitável, seu método de síntese, combinação de medicamento e uso dos mesmos | |
| BR112019005318A2 (pt) | compostos de aza-indazol para uso em lesões no tendão e/ou ligamento | |
| BR112016020260A8 (pt) | uso de um composto na fabricação de um medicamento para tratar uma doença colestática intra-hepática | |
| CR20170513A (es) | Derivados de pirazol útiles como inhibidores de proteína activadora de 5-li-poxigenasa (flap). | |
| BR112015019919A2 (pt) | compostos bicíclicos | |
| BR112019007543A2 (pt) | inibidores de ácido alfa-amino-beta-carboximuconico semialdeido decarboxilase | |
| BR112015007360A8 (pt) | Composição farmacêutica, e, método para a preparação de uma droga de combinação | |
| BR112016022749A2 (pt) | compostos de azole substituído por amido como inibidores de tnks1 e/ou tnks2 | |
| BR112015011515A2 (pt) | Composições farmacêuticas de inibidores de cetp | |
| BR112014007753A2 (pt) | composição farmacêutica granular |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |